Optimizing randomized phase II trials assessing tumor progression
Authors:
- Andrew StoneASAndrew Stone
- Catherine WheelerCWCatherine Wheeler
- Kevin CarrollKCKevin Carroll
- Alan BargeABAlan Barge
- 1 February 2007
- journal article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 28 (2) , 146-152
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Sample Size Calculations for Randomized Controlled TrialsEpidemiologic Reviews, 2002
- Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer VaccinesJournal of Clinical Oncology, 2001
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001
- Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study designCritical Reviews in Oncology/Hematology, 2000
- Development of Target-Based Antineoplastic AgentsInvestigational New Drugs, 2000
- Applicability of sample size calculations based on a comparison of proportions for use with the logrank testControlled Clinical Trials, 1985
- The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data1982